Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.80 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20777262 | 0.89 | CRBN (1.00) | CRBNANO1ROCK1DDB1 | |
| SCHEMBL20773497 | 0.89 | CRBN (1.00) | CRBNANO1ROCK1DDB1 | |
| SCHEMBL9269083 | 0.75 | KMT2A (0.62) | CRBNANO1ROCK1DDB1KCNQ2 | |
| SCHEMBL1844280 | 0.72 | CRBN (0.58) | CRBNANO1ROCK1KCNQ2MEN1 | |
| SCHEMBL26547565 | 0.72 | CRBN (0.62) | CRBNANO1ROCK1CYP1A2RECQL | |
| SCHEMBL26547568 | 0.72 | CRBN (0.62) | CRBNANO1ROCK1CYP1A2RECQL | |
| SCHEMBL20777315 | 0.70 | CRBN (0.54) | CRBNANO1ROCK1KCNQ2MEN1 | |
| SCHEMBL20777263 | 0.69 | CRBN (0.54) | CRBNANO1ROCK1KCNQ2MEN1 | |
| SCHEMBL30832854 | 0.69 | CRBN (0.56) | CRBNANO1ROCK1KCNQ2CYP1A2 | |
| SCHEMBL30832811 | 0.69 | CRBN (0.56) | CRBNANO1ROCK1KCNQ2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192643-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | CRBN, RBX1, ADRM1 | CRBN 1/4885ANO1 4710/4885ROCK1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.